Relmada Therapeutics, Inc.
RLMD
$3.74
-$0.31-7.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.09M | -9.87M | -17.56M | -18.66M | -21.73M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.59M | 3.44M | 4.26M | 6.97M | 7.52M |
| Change in Net Operating Assets | -221.40K | 24.90K | -4.77M | 2.89M | -2.45M |
| Cash from Operations | -6.72M | -6.40M | -18.07M | -8.80M | -16.66M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.75M | 6.68M | 15.36M | 11.35M | 16.14M |
| Cash from Investing | 6.75M | 6.68M | 15.36M | 11.35M | 16.14M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -73.00K | -- | -172.50K | -89.60K |
| Cash from Financing | 0.00 | -73.00K | -- | -172.50K | -89.60K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.10K | 203.60K | -2.71M | 2.37M | -602.50K |